Miromatrix Medical Inc.

NasdaqCM:MIRO Stock Report

Market Cap: US$93.0m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Miromatrix Medical Management

Management criteria checks 1/4

Miromatrix Medical's CEO is Jeff Ross, appointed in Jan 2017, has a tenure of 6.92 years. total yearly compensation is $1.16M, comprised of 47.3% salary and 52.7% bonuses, including company stock and options. directly owns 1.13% of the company’s shares, worth $1.05M. The average tenure of the management team and the board of directors is 1.8 years and 3.3 years respectively.

Key information

Jeff Ross

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage47.30%
CEO tenure6.9yrs
CEO ownership1.1%
Management average tenure1.8yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

Analysis Article • Oct 28

Miromatrix Medical (NASDAQ:MIRO) Will Have To Spend Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jul 01

We're A Little Worried About Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Mar 08

Here's Why We're A Bit Worried About Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Sep 30

Here's Why We're Watching Miromatrix Medical's (NASDAQ:MIRO) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Aug 25

Miromatrix gets US patent for recellularizing technology for use in organ transplant

Miromatrix Medical (NASDAQ:MIRO) said it has received a new patent from the U.S. Patent and Trademark Office for its perfusion decellularization and recellularization technology. The patent number 11,414,644 titled 'Methods of Recellularizing a Tissue or Organ for Improved Transplantability' covers the revascularization of decellularized organs and tissues which include all types of organs including liver, lung, kidney, and heart. The new patent expands the company's patent portfolio covering the bioengineering of transplantable organs, Miromatrix said in an Aug. 25 press release.
Seeking Alpha • Aug 15

Miromatrix Medical GAAP EPS of -$0.40 misses by $0.07, revenue of $3.95M

Miromatrix Medical press release (NASDAQ:MIRO): Q2 GAAP EPS of -$0.40 misses by $0.07. Revenue of $3.95M.

CEO Compensation Analysis

How has Jeff Ross's remuneration changed compared to Miromatrix Medical's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-US$27m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$30m

Dec 31 2022US$1mUS$550k

-US$30m

Sep 30 2022n/an/a

-US$28m

Jun 30 2022n/an/a

-US$26m

Mar 31 2022n/an/a

-US$21m

Dec 31 2021US$567kUS$425k

-US$15m

Sep 30 2021n/an/a

-US$10m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$323kUS$300k

-US$10m

Compensation vs Market: Jeff's total compensation ($USD1.16M) is above average for companies of similar size in the US market ($USD739.75K).

Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.

CEO

Jeff Ross (47 yo)

6.9yrs
Tenure
US$1,162,846
Compensation

Dr. Jeffrey James Ross, also known as Jeff, Ph D., serves as Chief Executive Officer of Miromatrix Medical Inc. since 2017 and its Director since October 2019. He serves as a Director of Reprise Biomedical...

Leadership Team

NamePositionTenureCompensationOwnership
Jeffrey Ross
CEO & Director6.9yrsUS$1.16m1.13%
$ 1.0m
James Douglas
CFO & Secretary1.8yrsUS$736.14kno data
Rodrigo Mesquita
Vice President of Manufacturing & Operationsless than a yearno datano data
Tom Emig
Vice President of People & Cultureno datano datano data
1.8yrs
Average Tenure

Experienced Management: MIRO's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Jeffrey Ross
CEO & Director4.2yrsUS$1.16m1.13%
$ 1.0m
John Erb
Independent Director6.7yrsUS$85.42k0.21%
$ 190.7k
Paul Buckman
Independent Chairman of the Board6.7yrsUS$145.42k0.19%
$ 178.3k
Peter Maag
Independent Director2.5yrsUS$95.42k0.22%
$ 201.1k
William Burke
Independent Director1.9yrsUS$268.76k0.22%
$ 209.0k
Lisa Heine
Independent Director1.9yrsUS$256.26k0.22%
$ 209.0k
3.3yrs
Average Tenure
57yo
Average Age

Experienced Board: MIRO's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/14 02:31
End of Day Share Price 2023/12/12 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Miromatrix Medical Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alexander NowakCraig-Hallum Capital Group LLC
Matthew O'BrienPiper Sandler Companies